Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSC-833, Daunorubicin, and Cytarabine in Older Patients With Newly Diagnosed AML
NCT00004217Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Feb 2000
- Primary completion
- May 2001
- Modality
- Peptides, Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of valspodar in acute myeloid leukemia (AML), sponsored by SWOG Cancer Research Network. Primary endpoint: Response Rate. Started Feb 2000; status: completed.
02
Drugs
valspodar
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00004217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004217.